GKSL clarifies discrepancies in financial results submission and XBRL data
GKSL clarifies discrepancies in financial results submission to NSE. The company addressed a delay in submission by stating a penalty was paid. Regarding XBRL discrepancies, GKSL resubmitted corrected standalone and consolidated cash flow statements, attributing the errors to inadvertent data entry.
This announcement is a routine clarification to the stock exchange regarding past submission errors and does not involve new financial performance, strategic changes, or significant corporate actions that would materially impact the company's stock.
The announcement is a clarification of past errors in financial reporting and does not contain new positive or negative financial information. It addresses regulatory queries and confirms corrective actions.
Gujarat Kidney And Super Speciality Limited (GKSL) has responded to an email from the National Stock Exchange of India Limited (NSE) dated 31/07/2026, seeking clarification regarding the submission of financial results. The company addressed two primary queries raised by the NSE.
Firstly, concerning the delay in submitting financial results within the stipulated time after the board meeting, GKSL stated that the penalty for this lapse was paid in April 2026. Secondly, the company addressed discrepancies found in the XBRL submission of financial results. Regarding the mention of half-yearly figures in the Standalone XBRL, GKSL asserted that the figures were correct to their knowledge but have refilled the XBRL utility afresh for resubmission. For the mismatch in the Consolidated Cash Flow Statement between XBRL and PDF, the company acknowledged an inadvertent data entry error and has corrected the figure, resubmitting the XBRL utility with the corrective action. GKSL expressed regret for the inconvenience caused by these inadvertent errors and assured the exchange of their commitment to comply with SEBI LODR Regulations.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.